123 related articles for article (PubMed ID: 2239937)
1. Etiology of hypercalcemia in hemodialysis patients on calcium carbonate therapy.
Meric F; Yap P; Bia MJ
Am J Kidney Dis; 1990 Nov; 16(5):459-64. PubMed ID: 2239937
[TBL] [Abstract][Full Text] [Related]
2. Effect of CAPD and hemodialysis on parathyroid function.
Malberti F; Corradi B; Imbasciati E
Adv Perit Dial; 1996; 12():239-44. PubMed ID: 8865912
[TBL] [Abstract][Full Text] [Related]
3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
4. Calcium carbonate is an effective phosphorus binder in children with chronic renal failure.
Andreoli SP; Dunson JW; Bergstein JM
Am J Kidney Dis; 1987 Mar; 9(3):206-10. PubMed ID: 3826069
[TBL] [Abstract][Full Text] [Related]
5. Calcium carbonate as a phosphate binder in dialysis patients: evaluation of an enteric-coated preparation and effect of additional aluminium hydroxide on hyperaluminaemia.
Ittel TH; Schäfer C; Schmitt H; Gladziwa U; Sieberth HG
Klin Wochenschr; 1991 Jan; 69(2):59-67. PubMed ID: 2027271
[TBL] [Abstract][Full Text] [Related]
6. Low dialysate calcium in continuous ambulatory peritoneal dialysis: a randomized controlled multicenter trial. The Peritoneal Dialysis Multicenter Study Group.
Weinreich T; Passlick-Deetjen J; Ritz E
Am J Kidney Dis; 1995 Mar; 25(3):452-60. PubMed ID: 7872324
[TBL] [Abstract][Full Text] [Related]
7. Substitution of calcium carbonate for aluminum hydroxide in patients on hemodialysis. Effects on acidosis, on parathyroid function, and on calcemia.
Anelli A; Brancaccio D; Damasso R; Padovese P; Gallieni M; Garella S
Nephron; 1989; 52(2):125-32. PubMed ID: 2500612
[TBL] [Abstract][Full Text] [Related]
8. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
9. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
[TBL] [Abstract][Full Text] [Related]
10. Long-term effects of calcium carbonate and 2.5 mEq/liter calcium dialysate on mineral metabolism.
Slatopolsky E; Weerts C; Norwood K; Giles K; Fryer P; Finch J; Windus D; Delmez J
Kidney Int; 1989 Nov; 36(5):897-903. PubMed ID: 2615197
[TBL] [Abstract][Full Text] [Related]
11. Effect of calcium carbonate combined with calcitonin on hypercalcemia in hemodialysis patients.
Wei Y; Kong XL; Li WB; Wang ZS
Ther Apher Dial; 2014 Dec; 18(6):618-22. PubMed ID: 24674384
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of long-term treatment with calcium carbonate as a phosphate binder.
Malberti F; Surian M; Poggio F; Minoia C; Salvadeo A
Am J Kidney Dis; 1988 Dec; 12(6):487-91. PubMed ID: 3143260
[TBL] [Abstract][Full Text] [Related]
13. Calcium carbonate is an effective phosphate binder when dialysate calcium concentration is adjusted to control hypercalcemia.
Mactier RA; Van Stone J; Cox A; Van Stone M; Twardowski Z
Clin Nephrol; 1987 Nov; 28(5):222-6. PubMed ID: 3427832
[TBL] [Abstract][Full Text] [Related]
14. Iatrogenic hypercalcemia in hemodialysis patients.
Muhammedi MA; Piraino B; Rault R; Johnston JR; Puschett JB
Clin Nephrol; 1991 Nov; 36(5):258-61. PubMed ID: 1752077
[TBL] [Abstract][Full Text] [Related]
15. Hypercalcaemia after oral calcium-carbonate therapy in patients on chronic haemodialysis.
Ginsburg DS; Kaplan EL; Katz AI
Lancet; 1973 Jun; 1(7815):1271-4. PubMed ID: 4126071
[No Abstract] [Full Text] [Related]
16. Effect of lanthanum carbonate vs. calcium carbonate on serum calcium in hemodialysis patients: a crossover study.
Toida T; Fukudome K; Fujimoto S; Yamada K; Sato Y; Chiyotanda S; Kitamura K
Clin Nephrol; 2012 Sep; 78(3):216-23. PubMed ID: 22874110
[TBL] [Abstract][Full Text] [Related]
17. Elevated bone aluminum and suppressed parathyroid hormone levels in hypercalcemic dialysis patients.
Piraino B; Chen T; Puschett JB
Am J Nephrol; 1989; 9(3):190-7. PubMed ID: 2757078
[TBL] [Abstract][Full Text] [Related]
18. Long-term (6 months) cross-over comparison of calcium acetate with calcium carbonate as phosphate binder.
Ben Hamida F; el Esper I; Compagnon M; Morinière P; Fournier A
Nephron; 1993; 63(3):258-62. PubMed ID: 8446261
[TBL] [Abstract][Full Text] [Related]
19. Low-calcium dialysis fluid and oral calcium carbonate in CAPD. A method of controlling hyperphosphataemia whilst minimizing aluminium exposure and hypercalcaemia.
Hutchison AJ; Freemont AJ; Boulton HF; Gokal R
Nephrol Dial Transplant; 1992; 7(12):1219-25. PubMed ID: 1337163
[TBL] [Abstract][Full Text] [Related]
20. Calcium set point progressively worsens in hemodialysis patients despite conventional oral 1-alpha hydroxycholecalciferol supplementation.
Ali AA; Varghese Z; Moorhead JF; Baillod RA; Sweny P
Clin Nephrol; 1993 Apr; 39(4):205-9. PubMed ID: 8491050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
